CytoSeek Revenue and Competitors

Bristol,

Location

N/A

Total Funding

Research

Industry

Estimated Revenue & Valuation

  • CytoSeek's estimated annual revenue is currently $612k per year.(i)
  • CytoSeek's estimated revenue per employee is $61,200

Employee Data

  • CytoSeek has 10 Employees.(i)
  • CytoSeek grew their employee count by -44% last year.

CytoSeek's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
Head Technical OperationsReveal Email/Phone
3
Director, CSOReveal Email/Phone
4
Senior Protein ScientistReveal Email/Phone
5
Principal scientist - T-cell engineeringReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$13M12743%N/AN/A
#2
$11.2M11062%N/AN/A
#3
$27.3M24310%N/AN/A
#4
$26M23725%$11MN/A
#5
$3.3M41-11%N/AN/A
#6
$11.6M11424%N/AN/A
#7
$1.6M225%N/AN/A
#8
$34.9M54818%N/AN/A
#9
$50.2M394-5%N/AN/A
#10
$13.6M243-10%N/AN/A
Add Company

What Is CytoSeek?

CytoSeek's mission is to use cell membrane augmentation technology to unlock the potential of next generation advanced therapies. We are a spinout company from the University of Bristol. Our novel cell membrane augmentation technology enables us to add new functionalities to cell therapies including tissue specific targeting and enhanced cell survivability. CytoSeek is engaged in proof of principle studies to demonstrate enhancement of cell therapies for cancer, heart disease, osteoarthritis and diabetic wound healing. We are looking to partner with cell therapy companies to bring these products to the clinic and ultimately enhance human health.

keywords:N/A

N/A

Total Funding

10

Number of Employees

$612k

Revenue (est)

-44%

Employee Growth %

N/A

Valuation

N/A

Accelerator

CytoSeek News

2022-03-22 - March: BrisEngBio | News and features

... Ventures having led investment rounds totalling £7.5 million and directly invested in two of those companies Imophoron and Cytoseek.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$0.9M10N/AN/A
#2
N/A10150%N/A
#3
$0.6M11-27%N/A
#4
$1.6M110%N/A
#5
$0.4M110%N/A